• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Healthcare, Regulatory and Reimbursement Landscape - Sweden - Product Image

Healthcare, Regulatory and Reimbursement Landscape - Sweden

  • ID: 2522574
  • March 2013
  • Region: Sweden
  • 197 pages
  • GlobalData

Healthcare, Regulatory and Reimbursement Landscape - Sweden

Summary

GlobalData, the industry analysis specialist, has released its new report “Healthcare, Regulatory and Reimbursement Landscape - Sweden”. The report is an essential source of information and analysis on Sweden’s healthcare, regulatory and reimbursement landscape. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory and reimbursement landscape and healthcare infrastructure. Most importantly, it provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. The report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by Our team of industry experts.

Sweden’s population was 9.6 million in 2012 and is increasing due to a positive balance between the birth and death rate, and immigration. Policymakers are additionally presented with the problem of an increasing unemployment rate due to a lack of clear monetary policies. The pharmaceutical market was estimated at $5.7 billion in 2011 and is expected to reach approximately READ MORE >

Note: Product cover images may vary from those shown

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Report Guidance
3 Overview of Pharmaceutical and Medical Device Markets
3.1 Pharmaceutical Market
3.1.1 Market Overview
3.1.2 Pharmaceutical Exports and Imports
3.1.3 Supply Channels
3.1.4 Market Segments
3.1.5 Major Therapeutic Areas
3.1.6 Major Players
3.2 Medical Device Market
3.2.1 Market Overview
3.2.2 Overview of Top Five Segments
3.2.3 Diagnostics Market
3.2.4 Major Players
3.3 Market Drivers and Barriers
3.3.1 Market Drivers
3.3.2 Market Barriers
4 Market Access
4.1 Reimbursement and Payer Landscape
4.1.1 Healthcare System
4.1.2 Reimbursement Process
4.1.3 Overview of Insurance Providers
4.1.4 Patient Share in Healthcare Spending
4.1.5 Pricing Policies
4.2 Regulatory Landscape
4.2.1 Overview of Regulatory Agencies
4.2.2 Drug Approval Process
4.2.3 New Medical Device Approval Process
4.2.4 Licensing Process for Manufacturing and Import of Pharmaceuticals
4.2.5 Licensing Process for Exports and Parallel Imports
4.2.6 Intellectual Property Rights Landscape
4.2.7 Clinical Trial Regulations
4.2.8 Pharmaceutical Advertising Regulations
4.2.9 Pharmacy Regulations
4.2.10 Labeling and Packing Regulations
5 Country Analysis
5.1 Political Environment
5.1.1 Political Structure
5.1.2 Analysis of the Current Political Environment
5.1.3 Healthcare Policy Initiatives
5.2 Economic Landscape
5.3 Economic Indicators
5.3.1 Gross Domestic Product
5.3.2 Gross National Income
5.3.3 Inflation
5.3.4 Currency Exchange Rate
5.3.5 Foreign Direct Investment
5.3.6 Foreign Exchange Reserves
5.3.7 Trade Balance
5.3.8 Government Structural Balance
5.3.9 Government Net Debt
5.3.10 Major Industries
5.4 Demographics
5.4.1 Population
5.4.2 Education and Literacy
5.4.3 Employment
5.4.4 Disease Burden
5.5 Healthcare Infrastructure
5.5.1 Healthcare Facilities
5.5.2 Healthcare Parameters
5.5.3 Environmental Health
5.5.4 Healthcare Personnel
5.6 Healthcare Expenditure
5.6.1 Overview
5.6.2 Major Components of Healthcare Spending
5.6.3 Public-Private Share
5.6.4 Spending in Pharmaceutical R&D
5.7 Trade Associations
5.7.1 SwedenBIO
5.7.2 Swedish Medtech
5.7.3 The Swedish Association of the Pharmaceutical Industry (LIF)
5.7.4 Swedish Association for Small and Medium-Sized Companies Active in R&D
5.7.5 Swedish Pharmacy Association
5.8 Trade Fairs
6 Opportunities and Challenges
6.1 Opportunities
6.2 Challenges
7 Appendix
7.1 Abbreviations
7.2 Bibliography
7.3 Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Expert Panel Validation
7.4 Contact Us
7.5 Disclaimer

1.1 List of Tables
Table 1: Pharmaceutical Market, Sweden, Revenue ($bn), 2007–2012
Table 2: Pharmaceutical Market, Sweden, Revenue Forecast ($bn), 2013–2020
Table 3: Pharmaceutical Exports, Sweden, Revenue ($bn), 2007–2012
Table 4: Pharmaceutical Imports, Sweden, Revenue ($bn), 2007–2012
Table 5: Pharmaceutical Market, Sweden, Pharmacy Mark-up Scheme for Prescription-only Medicines (SEK/€), 2006
Table 6: Pharmaceutical Market, Sweden, Pharmacy Mark-up Scheme for OTC Pharmaceuticals (SEK/€), 2006
Table 7: Generic Pharmaceutical Market, Sweden, Share (%) and Revenue ($m), 2007–2012
Table 8: Generic Pharmaceutical Market, Sweden, Share (%) and Revenue Forecast ($m), 2013–2020
Table 9: Pharmaceutical Market, Sweden, Change in Average Drug Price Paid (%), 2009
Table 10: Pharmaceutical Market, Global, Drugs Going Off-Patent, 2011–2014
Table 11: Pharmaceutical Market, EU, Biosimilars, Reference Products and Approval Dates, 2006–2010
Table 12: Over-The-Counter Pharmaceutical Market, Sweden, Revenue ($m), 2007–2012
Table 13: Over-The-Counter Pharmaceutical Market, Sweden, Revenue Forecast ($m), 2013–2020
Table 14: Major Therapy Areas, Sweden, Revenue ($m and SEKm), 2009–2011
Table 15: Major Therapeutic Areas, Sweden, Volume of Drugs Sold (‘000), 2009–2011
Table 16: Pfizer, Late-Stage Pipeline, 2013
Table 17: Novartis, Planned Filings, 2012 to = 2016
Table 18: Merck, Global, Major Products, Revenue ($m), 2011
Table 19: Merck, Late-Stage Pipeline, 2013
Table 20: AstraZeneca, Global, Major Products, Revenue ($m), 2011
Table 21: AstraZeneca, Late-Stage Pipeline, 2012
Table 22: Medical Device Market, Sweden, Revenue ($bn), 2007–2012
Table 23: Medical Device Market, Sweden, Revenue Forecast ($bn), 2013–2020
Table 24: Medical Device Market, Sweden, Revenue by Segment ($m), 2012
Table 25: Ophthalmic Device Market, Sweden, Revenue ($m), 2007–2012
Table 26: Ophthalmic Device Market, Sweden, Sales Trends for Major Players- ($m), 2011
Table 27: In Vitro Diagnostics Device Market, Sweden, Revenue ($m), 2007–2012
Table 28: In Vitro Device Market, Sweden, Sales Trends for Major Players- ($m), 2011
Table 29: Orthopedic Device Market, Sweden, Revenue ($m), 2007–2012
Table 30: Orthopedic Device Market, Sweden, Sales Trends for Major Players- (%), 2011
Table 31: Cardiovascular Device Market, Sweden, Revenue ($m), 2007–2012
Table 32: Cardiovascular Device Market, Sweden, Sales Trends for Major Players- ($m), 2011
Table 33: Diagnostic Imaging Device Market, Sweden, Revenue ($m), 2007–2012
Table 34: Diagnostic Imaging Device Market, Sweden, Sales Trends for Major Players- ($m), 2011
Table 35: Diagnostics Market, Sweden, Revenue ($m), 2007–2012
Table 36: Diagnostics Market, Sweden, Revenue Forecast ($m), 2013–2020
Table 37: Major Medical Device Companies, Sweden, Revenue ($m), 2010
Table 38: Siemens Healthcare, Major Products, Revenue ($m), 2012
Table 39: Siemens Healthcare, Late-Stage Pipeline, 2012
Table 40: Essilor International, Global, Major Segments, Revenue ($m), 2010
Table 41: Medtronic, Global, Major Products, Revenue ($m), 2011
Table 42: Roche, Global, Major Products, Revenue ($m), 2012
Table 43: Roche, Late-Stage Pipeline, 2012
Table 44: Reimbursement and Co-payment Rates, Sweden, 2011
Table 45: Subsidies on Dental Preventive Care and General Examination, Sweden, 2011
Table 46: User Charges for Health Services, Sweden, 2011
Table 47: Disability Allowance, Sweden (SEK), 2013
Table 48: Healthcare Spending, Sweden, Patient Share (%), 2007–2012
Table 49: Marketing Authorization for Medicinal Products, Sweden, Fees, 2012
Table 50: Marketing Authorization for Medicinal Products, Fees, Sweden, 2012
Table 51: Approval of Marketing Authorization for Medicinal Products, Sweden, Fee, 2012
Table 52: Annual Fees, Sweden, 2012
Table 53: Filing National Patents with PRV, Sweden, Optional Fees (SEK) ($), 2012
Table 54: New Trademark Registration, Sweden, PRV’s Online Service, Fee (SEK/$)
Table 55: GDP Per Capita ($), Sweden, 2007–2012
Table 56: GDP Per Capita ($), Sweden, Forecast, 2013–2020
Table 57: GDP, Sweden, Annual Growth (%), 2007–2012
Table 58: GDP, Sweden, Annual Growth (%), Forecast, 2013–2020
Table 59: GNI Per Capita ($), Sweden, 2007–2012
Table 60: Average Consumer Price Index, Sweden, 2007–2012
Table 61: Average Consumer Price Index, Sweden, Forecast, 2013–2020
Table 62: Average Consumer Price, Sweden, Annual Change (%), 2007–2012
Table 63: Average Consumer Price, Sweden, Annual Change Forecast (%), 2013–2020
Table 64: Currency Exchange Rate (SEK/$), Sweden, 2007–2012
Table 65: Foreign Direct Investment Net ($bn), Sweden, 2007–2012
Table 66: Foreign Exchange Reserves ($bn), Sweden, 2007–2012
Table 67: Exports of Goods and Service ($bn), Sweden 2007–2012
Table 68: Imports of Goods and Service ($bn), Sweden 2007–2012
Table 69: General Government Structural Balance ($bn), Sweden, 2007–2012
Table 70: General Government Structural Balance ($bn), Sweden, Forecast, 2013–2020
Table 71: General Government Net Debt ($bn), Sweden, 2007–2012
Table 72: General Government Net Debt ($bn), Sweden, Forecast, 2013–2020
Table 73: Major Industries, Sweden, Production ($bn), 2010
Table 74: Population (million), Sweden, 2007–2012
Table 75: Population (million), Sweden, Forecast, 2013–2020
Table 76: Urban and Rural Population, Sweden, Share (%), 2007–2012
Table 77: Urban and Rural Population, Sweden, Share (%), Forecast, 2013–2020
Table 78: Age Groups, Population Distribution (%), Sweden, 2007–2012
Table 79: Age Groups, Population Distribution (%), Sweden, 2013–2020
Table 80: Births (Per 1,000 Population) Sweden, 2007–2012
Table 81: Mortality Rate (Per 1,000 Population), Sweden, 2007–2012
Table 82: Major Causes of Mortality, Sweden, 2011
Table 83: Children <5 Years, Mortality Rate (Per 1,000 Live Births), Sweden, 2007–2012
Table 84: Immunization Rate (%), Sweden, 2007–2012
Table 85: Major Causes of Male Mortality, Sweden, 2011
Table 86: Major Causes of Female Mortality, Sweden, 2011
Table 87: Gender Ratio (M/F), Sweden, 2007–2012
Table 88: Life Expectancy at Birth (Years), Sweden, 2007–2012
Table 89: Levels of Education, Sweden, Gross Enrolment (%), 2010
Table 90: Unemployment Rate (%), Sweden, 2007–2012
Table 91: Healthcare Costs of Cardiovascular Disease, Sweden, ($m), 2009
Table 92: Healthcare Costs of Coronary Heart Disease, Sweden, ($m), 2009
Table 93: Major Diseases, Sweden, DALY (Per 100,000 Population), 2004
Table 94: Beds (Per 1,000 Population), Sweden, 2007–2012
Table 95: Beds (Per 1,000 Population), Sweden, Forecast 2013–2020
Table 96: Physicians (Per 1,000 Population), Sweden, 2007–2012
Table 97: Emission of CO2 (Million Tons), Sweden, 2007–2012
Table 98: PM10 (µg/m3), Sweden, 2007-2012
Table 99: Nurses (per 1,000 Population),Sweden, 2007–2012
Table 100: Pharmacists (Per 100,000 Population), Sweden, 2007–2012
Table 101: Dentists (Per 100,000 Population), Sweden, 2007–2012
Table 102: Healthcare Expenditure (% of GDP), Sweden, 2007–2012
Table 103: Healthcare Expenditure (% of GDP), Sweden, Forecast, 2013–2020
Table 104: Healthcare Expenditure, Sweden, Components (%), 2010
Table 105: Healthcare Expenditure, Sweden, Public-Private Share (%) 2007–2012
Table 106: Pharmaceutical R&D Expenditure ($bn), Sweden, 2007–2012
Table 107: Major Healthcare Trade Fairs, Sweden, 2013–2014

1.2 List of Figures
Figure 1: Pharmaceutical Market, Sweden, Revenue ($bn), 2007–2012
Figure 2: Pharmaceutical Market, Sweden, Revenue Forecast ($bn), 2013–2020
Figure 3: Pharmaceutical Exports, Sweden, Revenue ($bn), 2007–2012
Figure 4: Pharmaceutical Exports, Sweden, Trading Partners (%), 2011
Figure 5: Pharmaceutical Imports, Sweden, Revenue ($bn), 2007–2012
Figure 6: Pharmaceutical Imports, Sweden, Trading Partners, 2011
Figure 7: Pharmaceutical Market, Sweden, Distribution System, 2012
Figure 8: Generic Pharmaceutical Market, Sweden Revenue ($m), 2007–2012
Figure 9: Generic Pharmaceutical Market, Sweden, Revenue Forecast ($m), 2013–2020
Figure 10: Pharmaceutical Market, Sweden, Arthritis Treatments (‘000), 1999–2005
Figure 11: Over-The-Counter Pharmaceutical Market, Sweden, Revenue ($m), 2007–2012
Figure 12: Over-The-Counter Pharmaceutical Market, Sweden, Revenue Forecast ($m), 2013–2020
Figure 13: Major Therapeutic Areas, Sweden, Revenue ($m), 2009–2011
Figure 14: Major Therapeutic Areas, Sweden, Volume of Drugs Sold (‘000), 2009–2011
Figure 15: Medical Device Market, Sweden, Revenue ($bn), 2007–2012
Figure 16: Medical Device Market, Sweden, Revenue Forecast ($bn), 2013–2020
Figure 17: Medical Device Market, Sweden, Revenue by Segment ($m), 2012
Figure 18: Ophthalmic Device Market, Sweden, Revenue ($m), 2007–2012
Figure 19: Ophthalmic Device Market, Sweden, Sales Trends for Major Players- ($m), 2007–2011
Figure 20: In Vitro Diagnostics Device Market, Sweden, Revenue ($m), 2007–2012
Figure 21: In Vitro Diagnostics Device Market, Sweden, Sales Trends for Major Players- ($m), 2007–2011
Figure 22: Orthopedic Device Market, Sweden, Revenue ($m), 2007–2012
Figure 23: Orthopedic Device Market, Sweden, Sales Trends for Major Players- ($m), 2007–2011
Figure 24: Cardiovascular Device Market, Sweden, Revenue ($m), 2007–2012
Figure 25: Cardiovascular Device Market, Sweden, Sales Trends for Major Players- ($m), 2007–2011
Figure 26: Diagnostic Imaging Device Market, Sweden, Revenue ($m), 2007–2012
Figure 27: Diagnostic Imaging Device Market, Sweden, Sales Trends for Major Players- ($m), 2007–2011
Figure 28: Diagnostics Market, Sweden, Revenue ($m), 2007–2012
Figure 29: Diagnostics Market, Sweden, Revenue Forecast ($m), 2013–2020
Figure 30: Major Medical Device Companies, Sweden, Revenue ($m), 2010
Figure 31: Healthcare Market, Sweden, Drivers and Barriers, 2012
Figure 32: Healthcare Regulatory Framework, Sweden, 2012
Figure 33: Healthcare Framework, Sweden, 2012
Figure 34: Evolution of Major Healthcare Reforms, Sweden, 2000–2011
Figure 35: County Council Revenue, Sweden, Source (%), 2009
Figure 36: Financial Flow of Healthcare, Sweden, 2012
Figure 37: Pharmaceutical Pricing and Reimbursement Process, Sweden, 2012
Figure 38: Healthcare Spending, Sweden, Patient Share (%), 2007–2012
Figure 39: Medical Products Agency, Sweden, Structure, 2012
Figure 40: National Board of Health and Welfare, Sweden, 2012
Figure 41: Centralized Procedure for Marketing Authorization, EU, Pre-Submission, 2012
Figure 42: Centralized Procedure, EU, Marketing Authorization, Pre-Opinion Phase, 2012
Figure 43: Centralized Procedure, EU, Marketing Authorization, Post-Opinion Phase, 2012
Figure 44: Decentralized Procedure, EU, Marketing Authorization, 2012
Figure 45: Mutual Recognition Procedure, EU, Marketing Authorization, 2012
Figure 46: Conformity Assessment of Class I Medical Devices, EU, 2012
Figure 47: Conformity Assessment of Class IIa Medical Devices, EU, 2012
Figure 48: Conformity Assessment of Class IIb Medical Devices, EU, 2012
Figure 49: Conformity Assessment of Class III Medical Devices, EU, 2012
Figure 50: GDP Per Capita ($), Sweden, 2007–2012
Figure 51: GDP Per Capita ($), Sweden, Forecast, 2013–2020
Figure 52: GDP, Sweden, Annual Growth (%), 2007–2012
Figure 53: GDP, Sweden, Annual Growth (%), Forecast, 2013–2020
Figure 54: GNI Per Capita ($), Sweden, 2007–2012
Figure 55: Average Consumer Price Index, Sweden, 2007–2012
Figure 56: Average Consumer Price Index, Sweden, Forecast, 2013–2020
Figure 57: Average Consumer Price, Sweden, Annual Change (%), 2007–2012
Figure 58: Average Consumer Price, Sweden, Annual Change Forecast (%), 2013–2020
Figure 59: Currency Exchange Rate (SEK/$), Sweden, 2007–2012
Figure 60: Foreign Direct Investment ($bn), Sweden, 2007–2012
Figure 61: Foreign Exchange Reserves ($bn), Sweden, 2007–2012
Figure 62: Exports of Goods and Service ($bn), Sweden 2007–2012
Figure 63: Imports of Goods and Service ($bn), Sweden 2007–2012
Figure 64: General Government Structural Balance ($bn), Sweden, 2007–2012
Figure 65: General Government Structural Balance ($bn), Sweden, Forecast, 2013–2020
Figure 66: General Government Net Debt ($bn), Sweden, 2007–2012
Figure 67: General Government Net Debt ($bn), Sweden, Forecast, 2013–2020
Figure 68: Major Industries, Sweden, Production ($bn), 2010
Figure 69: Population (million), Sweden, 2007–2012
Figure 70: Population (million), Sweden, Forecast, 2013–2020
Figure 71: Urban and Rural Population, Sweden, Share (%), 2007–2012
Figure 72: Urban and Rural Population, Sweden, Share (%), Forecast, 2013–2020
Figure 73: Age Groups, Population Distribution (%), Sweden, 2007–2012
Figure 74: Age Groups, Population Distribution (%), Sweden, 2013–2020
Figure 75: Births (Per 1,000 Population) Sweden, 2007–2012
Figure 76: Mortality Rate (Per 1,000 Population), Sweden, 2007–2012
Figure 77: Major Causes of Mortality, Sweden, 2011
Figure 78: Children <5 Years, Mortality Rate (Per 1,000 Live Births), Sweden, 2007–2012
Figure 79: Immunization Rate (%), Sweden, 2007–2012
Figure 80: Major Causes of Male Mortality, Sweden, 2011
Figure 81: Major Causes of Female Mortality, Sweden, 2011
Figure 82: Gender Ratio (M/F), Sweden, 2007–2012
Figure 83: Life Expectancy at Birth (Years), Sweden, 2007–2012
Figure 84: Structure of Higher Education Qualifications, Sweden, 2012
Figure 85: Levels of Education, Sweden, Gross Enrolment (%), 2010
Figure 86: Unemployment Rate (%), Sweden, 2007–2012
Figure 87: Healthcare Costs of Cardiovascular Disease, Sweden, ($m), 2009
Figure 88: Healthcare Costs of Coronary Heart Disease, Sweden, ($m), 2009
Figure 89: Major Diseases, Sweden, DALY (Per 100,000 Population), 2004
Figure 90: Beds (Per 1,000 Population), Sweden, 2007–2012
Figure 91: Beds (Per 1,000 Population), Sweden, Forecast, 2013–2020
Figure 92: Physicians (Per 1,000 Population), Sweden, 2007–2012
Figure 93: Emission of CO2 (Million Tons), Sweden, 2007–2012
Figure 94: PM10 (µg/m3), Sweden, 2007-2012
Figure 95: Nurses (per 1,000 Population),Sweden, 2007–2012
Figure 96: Pharmacists (Per 100,000 Population), Sweden, 2007–2012
Figure 97: Dentists (Per 100,000 Population), Sweden, 2007–2012
Figure 98: Healthcare Expenditure (% of GDP), Sweden, 2007–2012
Figure 99: Healthcare Expenditure (% of GDP), Sweden, Forecast, 2013–2020
Figure 100: Healthcare Expenditure, Sweden, Components (%), 2010
Figure 101: Healthcare Expenditure, Sweden, Public-Private Share (%) 2007–2012
Figure 102: Pharmaceutical R&D Expenditure ($bn), Sweden, 2007–2012
Figure 103: Opportunities and Challenges, Healthcare Market, Sweden, 2012

Note: Product cover images may vary from those shown

Sweden’s Elderly Population Driving Pharmaceutical Market Growth

Life expectancy in Sweden is one of the highest in the world, implying an increasingly large elderly population in the future, and subsequent growth in demand for healthcare, states a new report by research and consulting firm The authors.

The new report* shows that healthcare for the elderly is already a priority in Sweden. National healthcare expenditure accounted for 9.8% of GDP in 2012, and the country’s allocation to elderly care stands far above the EU average in proportion to GDP. A total of SEK95.9 billion, (US$14 billion or €10.7 billion) was spent on healthcare for the elderly in 2010, and the Swedish government is investing a further SEK4.3 billion (US$0.6 billion or €0.5 billion) until 2014 to improve health and social care for the most infirm members of the elderly population.

Statistics demonstrate that over the next 35 years, the proportion of the Swedish population above the age of 65 will increase by almost 40%, and this will inevitably lead to higher taxes for the working population in order to meet inflating healthcare needs. Sustaining economic growth and quality healthcare will therefore become a challenge.

Sweden’s government bases its pharmaceutical pricing policy on drug effectiveness, with the value of pharmaceuticals judged in terms of extended patient life expectancy or significantly improved quality of life. In attempts to curb healthcare spending, the government also promotes mandatory generic substitution through the Pharmaceutical Benefits Scheme (PBS), allowing pharmacists to dispense the lowest priced generic substitute of any prescribed drug.

Generic drugs accounted for approximately US$882.5m in 2012, and the generics market is forecast to increase at a higher Compound Annual Growth Rate (CAGR) of 5.8% to reach US$1.4 billion in 2020. Generics have held a low revenue share of around 15% over the last few years due to their low price, but the price of branded products with high-volume sales fell by 80–95% over the same time period following patent expiries, showing the level of price competition between generic manufacturers. This will act to restrict market growth somewhat, and lead to a lack of innovation by pharmaceutical and biotechnology companies now unable to turn handsome profits, but this trend caters perfectly to Sweden’s need to cut healthcare costs.

The pharmaceutical market in Sweden was valued at US$5.7 billion in 2011, and is expected to grow at a CAGR of 2.6% to reach US$6.9 billion in 2020.

*Healthcare, Regulatory and Reimbursement Landscape – Sweden

This report is an essential source of information and analysis on Austria’s healthcare, regulatory and reimbursement landscape, identifying key trends in the healthcare market and providing insights into the demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by The authors’s team of industry experts.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos